制备和评估装有苄达明的阴道海绵,体外/体内研究

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Noha S El-Salamouni, Marwa A Yakout, Gihan S Labib, Ragwa M Farid
{"title":"制备和评估装有苄达明的阴道海绵,体外/体内研究","authors":"Noha S El-Salamouni, Marwa A Yakout, Gihan S Labib, Ragwa M Farid","doi":"10.1080/10837450.2024.2306803","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to design a new Benzydamine HCl (BNZ) suppo-sponge for controlled, mucoadhesive dosage form for vaginal candidiasis treatment, offering advantages over traditional creams, ointments, or gels. BNZ-loaded suppo-sponges were fabricated by simple casting / freeze-drying technique utilizing the cross-linking of chitosan (Cs) with vanillin (V). Vaginal suppo-sponges were prepared based on different vanillin cross-linking ratios (V).<sub>n</sub>), from 0 to 2%w/w. To best of our knowledge, this is the first study that uses Schiff's base between chitosan and vanillin as a drug delivery system to treat fungal vaginal infections. Schiff's base formation was confirmed by FT-IR. <i>In-vitro</i> appraisal showed acceptable physical and mechanical characteristics. Formulations based on cross-linking of Cs with V showed a more pronounced <i>in-vitro</i> antifungal activity. <i>In-vitro</i> drug release revealed a prolonged release pattern, becoming more noticeable with the higher cross-linked suppo-sponges (22.34% after 8 h). In-vivo testing of CsV<sub>2</sub> suppo-sponge indicated a more pronounced reduction in fungal count than both CsV<sub>0</sub> and Tantum<sup>®</sup> Rosa in the first week, with a peak reduction on day 7 and the 10<sup>th</sup> and 11<sup>th</sup> days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis. than both CsV<sub>0</sub> and Tantum<sup>®</sup> Rosa in the first week, with a peak reduction on day 7 and the 10<sup>th</sup> and 11<sup>th</sup> days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"86-97"},"PeriodicalIF":2.6000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preparation and evaluation of vaginal suppo-sponges loaded with benzydamine, <i>in-vitro/in-vivo study</i>.\",\"authors\":\"Noha S El-Salamouni, Marwa A Yakout, Gihan S Labib, Ragwa M Farid\",\"doi\":\"10.1080/10837450.2024.2306803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aimed to design a new Benzydamine HCl (BNZ) suppo-sponge for controlled, mucoadhesive dosage form for vaginal candidiasis treatment, offering advantages over traditional creams, ointments, or gels. BNZ-loaded suppo-sponges were fabricated by simple casting / freeze-drying technique utilizing the cross-linking of chitosan (Cs) with vanillin (V). Vaginal suppo-sponges were prepared based on different vanillin cross-linking ratios (V).<sub>n</sub>), from 0 to 2%w/w. To best of our knowledge, this is the first study that uses Schiff's base between chitosan and vanillin as a drug delivery system to treat fungal vaginal infections. Schiff's base formation was confirmed by FT-IR. <i>In-vitro</i> appraisal showed acceptable physical and mechanical characteristics. Formulations based on cross-linking of Cs with V showed a more pronounced <i>in-vitro</i> antifungal activity. <i>In-vitro</i> drug release revealed a prolonged release pattern, becoming more noticeable with the higher cross-linked suppo-sponges (22.34% after 8 h). In-vivo testing of CsV<sub>2</sub> suppo-sponge indicated a more pronounced reduction in fungal count than both CsV<sub>0</sub> and Tantum<sup>®</sup> Rosa in the first week, with a peak reduction on day 7 and the 10<sup>th</sup> and 11<sup>th</sup> days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis. than both CsV<sub>0</sub> and Tantum<sup>®</sup> Rosa in the first week, with a peak reduction on day 7 and the 10<sup>th</sup> and 11<sup>th</sup> days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis.</p>\",\"PeriodicalId\":20004,\"journal\":{\"name\":\"Pharmaceutical Development and Technology\",\"volume\":\" \",\"pages\":\"86-97\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Development and Technology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10837450.2024.2306803\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2024.2306803","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

与传统的药膏、软膏或凝胶相比,以可控方式释放局部给药的粘液黏附剂型在治疗念珠菌性阴道炎方面具有明显优势。这项研究旨在设计一种新型盐酸苄达明(BNZ)辅助海绵,用于治疗念珠菌性阴道炎。利用壳聚糖(Cs)与香兰素(V)的交联,通过简单的浇铸/冷冻干燥技术制成了含有 BNZ 的辅助海绵。根据不同的香兰素交联比例(Vn)(0-2%w/w)制备了阴道用海绵。据我们所知,这是首次使用壳聚糖和香兰素之间的希夫碱作为药物输送系统来治疗真菌阴道感染的研究。傅立叶变换红外光谱(FTIR)证实了希夫碱的成功形成。体外鉴定显示,其物理和机械特性均可接受。基于 Cs 与 V 交联的制剂显示出更明显的体外抗真菌活性。体外药物释放显示出延长的释放模式,交联度越高的支持海绵释放得越明显(8 小时后释放 22.34%)。CsV2 支持海绵的体内测试表明,与 CsV0 和 Tantum® Rosa 相比,CsV2 支持海绵在第一周能更明显地减少真菌数量,在第 7 天、第二周的第 10 天和第 11 天达到峰值。总之,壳聚糖/香兰素辅助海绵是一种用于局部治疗阴道念珠菌病的药物输送系统,具有广阔的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preparation and evaluation of vaginal suppo-sponges loaded with benzydamine, in-vitro/in-vivo study.

This study aimed to design a new Benzydamine HCl (BNZ) suppo-sponge for controlled, mucoadhesive dosage form for vaginal candidiasis treatment, offering advantages over traditional creams, ointments, or gels. BNZ-loaded suppo-sponges were fabricated by simple casting / freeze-drying technique utilizing the cross-linking of chitosan (Cs) with vanillin (V). Vaginal suppo-sponges were prepared based on different vanillin cross-linking ratios (V).n), from 0 to 2%w/w. To best of our knowledge, this is the first study that uses Schiff's base between chitosan and vanillin as a drug delivery system to treat fungal vaginal infections. Schiff's base formation was confirmed by FT-IR. In-vitro appraisal showed acceptable physical and mechanical characteristics. Formulations based on cross-linking of Cs with V showed a more pronounced in-vitro antifungal activity. In-vitro drug release revealed a prolonged release pattern, becoming more noticeable with the higher cross-linked suppo-sponges (22.34% after 8 h). In-vivo testing of CsV2 suppo-sponge indicated a more pronounced reduction in fungal count than both CsV0 and Tantum® Rosa in the first week, with a peak reduction on day 7 and the 10th and 11th days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis. than both CsV0 and Tantum® Rosa in the first week, with a peak reduction on day 7 and the 10th and 11th days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
2.90%
发文量
82
审稿时长
1 months
期刊介绍: Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信